In January 2026, the US Food and Drug Administration and the European Medicines Agency published ten joint guiding principles for good AI practice in drug development. The word that appears most frequently across those ten principles is not accuracy, efficiency, or innovation. It is traceable. The joint document states explicitly that data sources, processing steps, and decisions made by AI systems must be documented and traceable, and that models must be robust, explainable, and built on data that is fit for purpose.[3] The same month, the FDA-EMA joint release made one further expectation clear for pharmacovigilance teams: AI governance must be explainable, traceable, and inspection-ready, no different from any other GxP-regulated system. [1]
Traceable AI is not a marketing label or a feature category. It is a specific technical and governance standard that regulated industries, pharma above all others, now face as a regulatory requirement, an HTA body expectation, and an operational necessity. At Pienomial, traceability is the foundational architectural principle of our Knolens platform. Our KnolAI module is built from the ground up so that every output claim can be traced to a specific source at the sentence level. This post explains what traceable AI pharma means precisely, what the regulatory and HTA standards require, and why traceability is the single most important differentiator between AI tools that are safe for regulated pharma use and those that are not. [9]
1. The Definition: What Traceable AI Actually Means
Traceable AI is an AI system in which every output, decision, or recommendation can be traced back through a complete, verifiable chain of evidence to its original source. The chain has four links, and all four must be intact for the system to be genuinely traceable. [6]
Link 1, Source to knowledge base: The primary source document, whether a clinical trial publication, a regulatory filing, an HTA decision document, or a RWE study, was ingested into the knowledge base through a validated extraction process with documented methodology.
Link 2, Knowledge base to retrieval: The specific entity-relationship triple retrieved to generate the output is identified and logged. The user can see which fact was retrieved, from which source, at which location within the source document.
Link 3, Retrieval to output: The output claim generated from the retrieved fact is linked to that specific retrieved triple. The user can see that the claim in the output corresponds to the specific retrieved fact, not to a language model's probabilistic approximation of the fact. [7]
Link 4, Output to audit trail: Every step in the chain, from source ingestion to retrieval to output generation, is logged in a timestamped, tamper-evident audit trail that an external reviewer, whether a NICE technical reviewer, an FDA inspector, or a G-BA scientific advisor, can verify independently.
An AI system that cannot demonstrate all four links is not a traceable AI pharma system. It may be accurate, it may be fast, and it may produce fluent outputs. But it cannot satisfy the regulatory, HTA, or GxP traceability requirements that pharma teams face in 2026.
2. The Regulatory Backdrop: Why Traceability Became Non-Negotiable in 2026
The regulatory landscape for AI in drug development has changed more in the twelve months from January 2025 to January 2026 than in the preceding five years combined.
In January 2025, the FDA released its first draft guidance specifically addressing the application of AI in regulatory decision-making for pharmaceuticals and biological products. The guidance established a risk-based credibility assessment framework requiring AI systems used in regulatory applications to demonstrate data provenance, transparency, bias control, and traceable documentation. The EMA published its AI reflection paper in September 2024, emphasising patient safety through lifecycle oversight and explicit requirements for explainability. The EU AI Act, classifying pharmaceutical AI systems as high-risk, added conformity assessment requirements and mandated traceable documentation of data acquisition and transformation, explicit assessment of data representativeness, and strategies to address class imbalances and potential discrimination.
The FDA-EMA joint publication of ten good AI practice principles in January 2026 marked the point at which global regulatory alignment on AI traceability became explicit. The ten principles are not yet binding requirements, but they form the common reference point that all future FDA and EMA guidance will build upon.For pharma teams deploying AI in research, evidence generation, and regulatory submission workflows now, the implication is clear: AI systems must be traceable by design, because the regulatory framework being built will require it.
3. What NICE, G-BA, and IQWiG Now Require for AI-Assisted Submissions
The HTA body traceability requirements parallel the regulatory requirements and in some cases exceed them in specificity.
NICE published its formal position statement on AI in evidence generation in 2024, requiring that submissions using AI methods apply the PALISADE checklist developed by ISPOR's machine learning task force for transparency in methods development and findings, and the TRIPOD+AI checklist for reporting studies involving prediction modelling. NICE also specifies the Algorithmic Transparency Reporting Standard developed by the UK's Central Digital and Data Office. The statement makes clear that submitting organisations are responsible for ensuring that AI methods are consistent with applicable regulatory and ethical standards, and that the organisation, not the AI tool developer, bears accountability for all submitted content. Submissions that use AI without traceable methodology documentation will fail this requirement.
IQWiG, the German HTA scientific advisory body, applies its standard transparency requirements to AI-assisted evidence work without modification. The G-BA dossier must contain sufficient detail for an independent reviewer to assess the credibility of the literature search, screening, and data extraction process. AI tools whose methodology cannot be independently reproduced fail this standard.
For the EU JCA, which runs in parallel with EMA review with a three-month submission window, traceability requirements are embedded in the JCA dossier template's methodology documentation requirements. The rapid timeline and the multi-country assessor pool make transparent, reproducible AI methodology documentation not just a compliance requirement but an operational necessity: assessors from multiple EU member states reviewing the same dossier need to be able to independently verify the evidence chain.
4. The Black Box Problem: Why Standard AI Tools Cannot Be Traceable
The fundamental reason that most AI tools cannot satisfy pharma traceability requirements is architectural. Large language models generate text by predicting the most probable next token based on patterns in training data. The generation process is inherently probabilistic and non-deterministic. The same query may produce different outputs in different sessions. The specific training data patterns that influenced a specific output cannot be identified after generation. The relationship between a retrieved document and an output claim cannot be verified at the claim level.
This is what the HTA research community calls the black box bottleneck in AI-assisted submissions. A 2025 scoping review examined AI-based tools applied in HTA processes and found that transparency, human supervision, and open-source availability were systematically underaddressed. The review identified that the black-box nature of AI models adds layers of complexity to the transparency requirements that HTA bodies consider foundational to their assessment processes.
Retrieval-Augmented Generation improves on ungrounded language models by providing retrieved context, but it does not solve the traceability problem at the claim level. An LLM generating text from retrieved documents can still misattribute claims across documents, generate relationships between retrieved facts that do not exist in any single source, and produce plausible-sounding claims that fill gaps in the retrieved context. The retrieved document is logged. The specific claim-to-source relationship is not. This is why RAG-based AI tools, despite their retrieved context, cannot satisfy claim-level traceability requirements for HTA and regulatory submissions.
5. The Architecture of Traceable AI: How KnolAI Delivers It
At Pienomial, we describe KnolAI's traceability architecture as the glass box model: every input, every processing step, and every output is visible, verifiable, and documented. The architecture has three components that together guarantee claim-level traceability.
Component 1, Sourced knowledge graph with validated ingestion: KnolAI operates on the Knolens knowledge graph, where every entity-relationship triple is extracted from a specific primary source, validated before ingestion, and stored with its full provenance: source document, author, publication date, and specific location within the document at the paragraph or table level. There are no unsourced facts in the Knolens knowledge graph. Every fact has a verifiable origin.
Component 2, Deterministic retrieval with claim-level logging: When KnolAI answers a query, it traverses the knowledge graph to retrieve the specific entity-relationship triples that answer the query. The retrieval is deterministic: the same query returns the same facts from the same sources. Every retrieved triple is logged: which triple was retrieved, from which source, at which location. The retrieval log is part of the audit trail.
Component 3, Output generation constrained to retrieved facts: KnolAI generates natural language output from retrieved triples. The LLM is used only to convert structured retrieved facts into readable prose. It cannot introduce claims beyond what the retrieved triples contain. Every claim in the output is linked to the specific triple from which it was generated. The output includes embedded source citations at the claim level, not as a general reference list but as specific links from each claim to its source triple and its source document location.
6. The Audit Trail: What Complete Traceability Looks Like in Practice
A complete audit trail for a KnolAI research workflow covers every action from query initiation to output delivery. For a HEOR team using KnolAI to generate a systematic literature review evidence table, the audit trail includes the PICOS framework definition with timestamp, the search strings executed across each database with execution date and time, the deduplication algorithm and the count of duplicates removed, each abstract screening decision with the specific inclusion or exclusion criterion applied, each full-text screening decision with exclusion reason at the record level, each data extraction operation with the specific source location extracted from, and the output generation step with the specific retrieved triples that produced each output claim.
This audit trail is not a post-hoc summary. It is a live, timestamped record generated in parallel with every action the system takes. It satisfies FDA 21 CFR Part 11 requirements for electronic records in regulated processes, the NICE 2024 position statement's requirement for documentation of human oversight at each AI-assisted stage, and the ALCOA++ data integrity standards that apply to GxP systems in pharmacovigilance and quality management.For a NICE reviewer who asks to see the methodology documentation for an AI-assisted SLR, the audit trail from KnolAI is the complete, verifiable methodology record.
7. Traceable AI for Competitive Intelligence and Regulatory Landscape Analysis
The traceability requirement does not apply only to systematic literature reviews and HTA dossier sections. Any AI output that influences a pharma strategic decision, whether a competitive intelligence brief, a regulatory landscape analysis, or a market access scenario plan, carries the same implicit traceability obligation.
A pharma competitive intelligence brief that cites a competitor's Phase III readout data must be traceable to the specific source from which that data was extracted. If a CI analyst distributes a brief to senior leadership that contains an incorrect efficacy figure from a competitor trial, and that incorrect figure influences a portfolio investment decision, the question of where the number came from is not hypothetical.
KnolAI's traceability architecture covers competitive intelligence and regulatory landscape outputs with the same claim-level provenance that it applies to systematic literature review and HTA evidence synthesis. Every competitive intelligence claim in a KnolAI output links to its specific source: the specific clinical trial registry entry, regulatory filing document, or conference abstract from which the data was extracted, with timestamp and document location. For CI teams preparing briefings for board-level strategic decisions, this is not an audit compliance feature. It is the difference between intelligence you can stand behind and intelligence that requires a disclaimer.
8. The ALCOA++ Standard: What GxP Traceability Requires
ALCOA++ is the data integrity standard applied to GxP-regulated systems in pharmaceutical quality management and pharmacovigilance. The acronym covers: Attributable, meaning every data point has an identified author or system of origin; Legible, meaning data is readable and permanent; Contemporaneous, meaning data is recorded at the time of the activity; Original, meaning data is preserved in its original form; Accurate, meaning data is correct and truthful; plus the extended requirements of Complete, meaning all data is present; Consistent, meaning data is internally coherent; Enduring, meaning data is durable and permanently available; and Available, meaning data is accessible when needed.
The ALCOA++ standard maps directly to the audit trail requirements for AI-assisted pharma workflows. An AI system whose outputs do not carry attributable, contemporaneous, original documentation of how each output was generated does not meet ALCOA++ and cannot be deployed in GxP-regulated pharmacovigilance, quality management, or regulatory submission preparation workflows. KnolAI's audit trail satisfies all eight ALCOA++ dimensions by architectural design, not through post-generation documentation.[9]
9. How Fast Can Your Team Deploy Traceable AI with KnolAI?
Deploying traceable AI pharma capability with KnolAI does not require months of validation work before you see governed, attributed outputs. KnolAI ships as a pre-built product within the Knolens platform, with the traceability architecture, audit trail system, and claim-level attribution framework built in from day one. Most pharma teams are running their first fully traceable intelligence outputs within two weeks of onboarding.
Sprint 1, Weeks 1 to 2, First traceable outputs live: KnolAI is connected to your indication scope. The knowledge graph is active with pre-loaded clinical, regulatory, and HTA content for your therapeutic area. Your team runs the first queries and receives outputs with embedded claim-level source links and a complete audit trail. Every claim is traceable from the first session. No additional configuration required.
Sprint 2, Weeks 3 to 4, PRISMA, PALISADE, and TRIPOD+AI compliance configured: The NICE, G-BA, and ICER submission documentation frameworks are configured for your primary use cases. PALISADE and TRIPOD+AI checklist completion is automated from the audit trail data. The methodology documentation package that NICE requires for AI-assisted submissions is generated automatically from the KnolAI action log.
Sprint 3, Weeks 5 to 6, GxP validation and ALCOA++ compliance live: For teams using KnolAI in GxP-regulated pharmacovigilance or quality management workflows, the 21 CFR Part 11 validation package is reviewed and confirmed. The ALCOA++ audit trail is active and producing contemporaneous, attributed records for every KnolAI action. The traceability infrastructure is inspection-ready from this sprint forward.
Conclusion
Traceable AI is not a future regulatory requirement that pharma teams need to prepare for. It is a present requirement that FDA, EMA, NICE, and G-BA are already applying to AI-assisted evidence generation and regulatory submissions. The joint FDA-EMA good AI practice principles of January 2026, the NICE PALISADE and TRIPOD+AI requirements, and the EU AI Act's conformity assessment obligations for high-risk healthcare AI each enforce the same standard: AI outputs used in regulated pharma contexts must be fully traceable from source to claim.
At Pienomial, we built traceability into KnolAI as the foundational architectural constraint, not as a compliance feature. We believe that in regulated life sciences, the only AI that is actually trustworthy is AI whose every output can be verified against its source. That is what traceable AI pharma means, and it is what Knolens delivers from day one.
CTA: See KnolAI's traceability architecture in action. Book a demo with the Pienomial team.
